Sara Mangsbo
Overview
Explore the profile of Sara Mangsbo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
422
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Havervall S, Ng H, Falk A, Greilert-Norin N, Manberg A, Marking U, et al.
J Intern Med
. 2021 Aug;
291(1):72-80.
PMID: 34459525
Background: Emerging data support detectable immune responses for months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination, but it is not yet established to what degree and...
12.
Havervall S, Marking U, Greilert-Norin N, Ng H, Gordon M, Salomonsson A, et al.
EBioMedicine
. 2021 Aug;
70:103523.
PMID: 34391088
Background: Recent reports demonstrate robust serological responses to a single dose of messenger RNA (mRNA) vaccines in individuals previously infected with SARS-CoV-2. Data on immune responses following a single-dose adenovirus-vectored...
13.
Backman M, La Fleur L, Kurppa P, Djureinovic D, Elfving H, Brunnstrom H, et al.
J Pathol
. 2021 Aug;
255(3):243-256.
PMID: 34339045
Immune cells of the tumor microenvironment are central but erratic targets for immunotherapy. The aim of this study was to characterize novel patterns of immune cell infiltration in non-small cell...
14.
Napoleone A, Lauren I, Linkgreim T, Dahllund L, Persson H, Andersson O, et al.
N Biotechnol
. 2021 Jul;
65:9-19.
PMID: 34273575
The transition from preclinical biological drug development into clinical trials requires an efficient upscaling process. In this context, bispecific antibody drugs are particularly challenging due to their propensity to form...
15.
Cuzzubbo S, Mangsbo S, Nagarajan D, Habra K, Pockley A, McArdle S
Front Immunol
. 2021 Mar;
11:615240.
PMID: 33679703
Although the discovery and characterization of multiple tumor antigens have sparked the development of many antigen/derived cancer vaccines, many are poorly immunogenic and thus, lack clinical efficacy. Adjuvants are therefore...
16.
Nasi A, McArdle S, Gaudernack G, Westman G, Melief C, Rockberg J, et al.
Toxicol Rep
. 2020 Jul;
7:768-771.
PMID: 32632359
During the current COVID-19 pandemic, a need for evaluation of already available drugs for treatment of the disease is crucial. Hereby, based on literature review from the current pandemic and...
17.
Backman M, La Fleur L, Kurppa P, Djureinovic D, Elfving H, Brunnstrom H, et al.
J Thorac Oncol
. 2020 Feb;
PMID: 32028050
This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can...
18.
Eltahir M, Persson H, Mangsbo S
Expert Opin Biol Ther
. 2020 Jan;
20(3):215-217.
PMID: 31920122
No abstract available.
19.
Ibarra C, Karlsson M, Codeluppi S, Varas-Godoy M, Zhang S, Louhivuori L, et al.
Mol Oncol
. 2018 Oct;
13(2):202-211.
PMID: 30358081
Bacillus Calmette-Guérin (BCG) is widely used in the clinic to effectively treat superficial urinary bladder cancer. However, a significant proportion of patients who fail to respond to BCG risk cystectomy...
20.
Loskog A, Maleka A, Mangsbo S, Svensson E, Lundberg C, Nilsson A, et al.
Br J Cancer
. 2016 Apr;
114(8):872-80.
PMID: 27031851
Background: Current approaches for treating metastatic malignant melanoma (MM) are not effective enough and are associated with serious adverse events. Due to its immunogenicity, melanoma is an attractive target for...